Medable Inc. Unveils Next-Generation Digital Oncology Trial Platform
Palo Alto, CA – Medable Inc., a leading developer of clinical development and electronic Clinical Outcome Assessment (eCOA) technology, has announced a revolutionary digital oncology trial solution aimed at simplifying the operational complexities faced by sites and sponsors. Designed with the needs of vulnerable cancer patients and their caregivers in mind, this innovative platform provides accessible digital tools to enhance trial participation.
Oncology trials have become increasingly intricate, influenced by advances in precision medicine, biomarker utilization, and the necessity for engaging diverse patient populations. This complexity presents challenges in trial design and patient recruitment. In response, the FDA has been emphasizing the use of electronic Patient-Reported Outcomes (ePROs) in oncology trials to understand patient experiences related to symptoms and quality of life.
Medable’s latest oncology solution harnesses artificial intelligence, automation, and unique eCOA capabilities, enabling real-time data capture and remote trial participation. By streamlining processes for sites managing multiple studies, as well as sponsors and contract research organizations (CROs), Medable places the patient’s experience at the forefront of research, transforming lived experiences into valuable data to drive breakthroughs in cancer treatment.
With applications across all four phases of clinical research, Medable’s digital trial platform employs AI-driven eCOA technology, facilitating high-quality data collection while supporting patient flexibility and providing continuous oversight—critical for a vulnerable patient demographic. By digitizing assessments and enabling remote participation, the platform significantly reduces the burden on cancer patients, often immunocompromised or fatigued.
“Medable’s digital trial platform ensures that every patient’s voice is heard,” said Musaddiq Khan, VP of Customer Value and Oncology Lead at Medable. “We aim to tackle the major challenges in oncology trials, enhancing speed and clarity.”
For more information, visit Medable at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, Booth #10105, from May 30 to June 3 in Chicago.
————————————————————————
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
————————————————————————
